Juniper Pharmaceuticals Company Profile (NASDAQ:JNP)

About Juniper Pharmaceuticals (NASDAQ:JNP)

Juniper Pharmaceuticals logoJuniper Pharmaceuticals, Inc. is a women's health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women's health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company's commercialized product. The service segment includes product development, clinical trial manufacturing, and advanced analytical and consulting services, as well as characterizing and developing its pharmaceutical product candidates. The Company's pipeline of proprietary products includes JNP-0101, JNP-0201 and JNP-0301. JNP-0101 is developed to deliver oxybutynin for the treatment of overactive bladder in women. JNP-0201 is being designed to deliver natural hormones locally to vaginal tissue. JNP-0301 is being developed for the prevention of pre-term birth in women with a short cervical length. CRINONE is developed as a progesterone gel.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:JNP
  • CUSIP: N/A
  • Web:
  • Market Cap: $49.88 million
  • Outstanding Shares: 10,844,000
Average Prices:
  • 50 Day Moving Avg: $4.55
  • 200 Day Moving Avg: $4.60
  • 52 Week Range: $3.65 - $6.40
  • Trailing P/E Ratio: 5.88
  • Foreward P/E Ratio: 30.33
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $57.69 million
  • Price / Sales: 0.86
  • Book Value: $3.72 per share
  • Price / Book: 1.22
  • EBITDA: $9.49 million
  • Net Margins: 13.94%
  • Return on Equity: 21.49%
  • Return on Assets: 14.40%
  • Debt-to-Equity Ratio: 0.08%
  • Current Ratio: 2.17%
  • Quick Ratio: 1.85%
  • Average Volume: 23,698 shs.
  • Beta: 0.24
  • Short Ratio: 8.07

Frequently Asked Questions for Juniper Pharmaceuticals (NASDAQ:JNP)

What is Juniper Pharmaceuticals' stock symbol?

Juniper Pharmaceuticals trades on the NASDAQ under the ticker symbol "JNP."

How were Juniper Pharmaceuticals' earnings last quarter?

Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) announced its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.03) EPS for the quarter, beating the Zacks' consensus estimate of ($0.13) by $0.10. The firm had revenue of $13.96 million for the quarter, compared to analyst estimates of $11.84 million. Juniper Pharmaceuticals had a return on equity of 21.49% and a net margin of 13.94%. View Juniper Pharmaceuticals' Earnings History.

When will Juniper Pharmaceuticals make its next earnings announcement?

Juniper Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for Juniper Pharmaceuticals.

Where is Juniper Pharmaceuticals' stock going? Where will Juniper Pharmaceuticals' stock price be in 2017?

3 analysts have issued 12-month price targets for Juniper Pharmaceuticals' shares. Their forecasts range from $12.00 to $34.00. On average, they expect Juniper Pharmaceuticals' share price to reach $23.00 in the next year. View Analyst Ratings for Juniper Pharmaceuticals.

Who are some of Juniper Pharmaceuticals' key competitors?

Who are Juniper Pharmaceuticals' key executives?

Juniper Pharmaceuticals' management team includes the folowing people:

  • James A. Geraghty, Independence Chairman of the Board
  • Alicia Secor, Chief Executive Officer, Director
  • Jeffrey E. Young, Senior Vice President, Finance, Chief Financial Officer, Treasurer and Secretary (Principal Financial and Accounting Officer)
  • Nikin Patel, Chief Operating Officer, Director
  • Jennifer L. Good, Director
  • Frank Murdoch Armstrong, Independent Director
  • Cristina Csimma Pharm.D., Independent Director
  • Mary Ann Gray Ph.D., Independent Director
  • Ann Merrifield, Independent Director

How do I buy Juniper Pharmaceuticals stock?

Shares of Juniper Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Juniper Pharmaceuticals' stock price today?

One share of Juniper Pharmaceuticals stock can currently be purchased for approximately $4.55.

MarketBeat Community Rating for Juniper Pharmaceuticals (NASDAQ JNP)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  106 (Vote Outperform)
Underperform Votes:  115 (Vote Underperform)
Total Votes:  221
MarketBeat's community ratings are surveys of what our community members think about Juniper Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Juniper Pharmaceuticals (NASDAQ:JNP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $23.00 (405.49% upside)
Consensus Price Target History for Juniper Pharmaceuticals (NASDAQ:JNP)
Price Target History for Juniper Pharmaceuticals (NASDAQ:JNP)
Analysts' Ratings History for Juniper Pharmaceuticals (NASDAQ:JNP)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/14/2017BMO Capital MarketsUpgradeMarket Perform -> Outperform$31.00 -> $34.00LowView Rating Details
5/15/2017HC WainwrightReiterated RatingHoldN/AView Rating Details
5/6/2017Roth CapitalSet Price TargetBuy$12.00LowView Rating Details
8/18/2016Northland SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for Juniper Pharmaceuticals (NASDAQ:JNP)
Earnings by Quarter for Juniper Pharmaceuticals (NASDAQ:JNP)
Earnings History by Quarter for Juniper Pharmaceuticals (NASDAQ JNP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017($0.14)N/AView Earnings Details
8/3/2017Q2 2017($0.13)($0.03)$11.84 million$13.96 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.09)($0.13)$11.27 million$11.25 millionViewListenView Earnings Details
3/7/2017Q4 2016$0.45$0.88$15.33 million$20.93 millionViewListenView Earnings Details
11/15/2016Q3 2016($0.15)$0.02$10.58 million$11.56 millionViewN/AView Earnings Details
8/4/2016Q216($0.08)($0.16)$9.49 million$11.89 millionViewN/AView Earnings Details
5/4/2016Q116($0.08)$0.03$9.13 million$12.10 millionViewN/AView Earnings Details
3/10/2016Q415($0.02)($0.19)$7.89 million$7.60 millionViewN/AView Earnings Details
11/10/2015Q315($0.05)$0.09$7.10 million$11.50 millionViewN/AView Earnings Details
8/4/2015Q215($0.02)($0.03)$8.35 million$10.20 millionViewN/AView Earnings Details
5/6/2015Q115$0.04$0.07$7.80 million$8.30 millionViewN/AView Earnings Details
3/18/2015Q414$0.07($0.05)$7.93 million$7.30 millionViewN/AView Earnings Details
10/28/2014Q314$0.12$0.34$9.74 million$11.50 millionViewN/AView Earnings Details
7/31/2014Q2$0.11$0.01$6.86 millionViewN/AView Earnings Details
3/5/2014Q413$0.08$7.10 million$7.80 millionViewN/AView Earnings Details
11/7/2013Q313$0.16$0.20$6.75 million$7.10 millionViewN/AView Earnings Details
8/7/2013Q2 2013$0.02$0.03$6.50 million$7.02 millionViewN/AView Earnings Details
5/9/2013Q1 2013$0.03$0.01$6.50 million$6.30 millionViewN/AView Earnings Details
3/14/2013Q4 2012$0.02$0.03$7.60 million$6.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Juniper Pharmaceuticals (NASDAQ:JNP)
Current Year EPS Consensus Estimate: $-0.45 EPS
Next Year EPS Consensus Estimate: $0.15 EPS


Dividend History for Juniper Pharmaceuticals (NASDAQ:JNP)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Juniper Pharmaceuticals (NASDAQ:JNP)
Insider Ownership Percentage: 11.60%
Institutional Ownership Percentage: 36.20%
Insider Trades by Quarter for Juniper Pharmaceuticals (NASDAQ:JNP)
Institutional Ownership by Quarter for Juniper Pharmaceuticals (NASDAQ:JNP)
Insider Trades by Quarter for Juniper Pharmaceuticals (NASDAQ:JNP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/17/2017James A GeraghtyDirectorBuy2,000$4.82$9,640.00View SEC Filing  
9/13/2016James A GeraghtyDirectorBuy2,000$5.97$11,940.00View SEC Filing  
8/31/2016George ElstonCFOBuy1,000$5.50$5,500.00View SEC Filing  
8/26/2016C Ann MerrifieldDirectorBuy2,000$5.63$11,260.00View SEC Filing  
8/25/2016Alicia SecorInsiderBuy5,000$5.75$28,750.00View SEC Filing  
8/23/2016James A GeraghtyDirectorBuy7,000$5.96$41,720.00View SEC Filing  
12/4/2015C Ann MerrifieldDirectorBuy1,600$12.14$19,424.00View SEC Filing  
11/19/2015Nikin PatelCOOBuy5,000$11.82$59,100.00View SEC Filing  
11/18/2015Frank Condella JrCEOBuy5,000$11.68$58,400.00View SEC Filing  
8/14/2015C Ann MerrifieldDirectorBuy3,000$9.90$29,700.00View SEC Filing  
6/15/2015Frank M ArmstrongDirectorBuy1,255$7.95$9,977.25View SEC Filing  
6/9/2015Nikin PatelCOOBuy13,500$7.52$101,520.00View SEC Filing  
5/8/2015Frank Condella JrCEOBuy10,000$7.36$73,600.00View SEC Filing  
11/20/2014Donald H HunterDirectorBuy1,000$5.98$5,980.00View SEC Filing  
8/13/2014Frank Condella JrCEOBuy10,000$5.98$59,800.00View SEC Filing  
5/5/2014Frank Condella JrCEOBuy10,000$6.65$66,500.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Juniper Pharmaceuticals (NASDAQ:JNP)
Latest Headlines for Juniper Pharmaceuticals (NASDAQ:JNP)
DateHeadline logoJuniper Pharmaceuticals Inc (JNP) Delivered A Better ROE Than The Industry, Here’s Why - October 20 at 1:43 AM logoETFs with exposure to Juniper Pharmaceuticals, Inc. : October 18, 2017 - October 18 at 3:30 PM logoZacks: Analysts Anticipate Juniper Pharmaceuticals, Inc. (JNP) Will Announce Quarterly Sales of $11.98 Million - October 18 at 5:42 AM logoCritical Review: Juniper Pharmaceuticals (JNP) versus Its Competitors - October 12 at 4:32 AM logoETFs with exposure to Juniper Pharmaceuticals, Inc. : October 3, 2017 - October 5 at 5:32 AM logoJuniper Pharmaceuticals, Inc. (JNP) Receives Consensus Recommendation of "Buy" from Analysts - October 1 at 10:48 PM logo-$0.17 Earnings Per Share Expected for Juniper Pharmaceuticals, Inc. (JNP) This Quarter - September 27 at 10:20 PM logoJuniper Pharmaceuticals (JNP) vs. Its Peers Critical Contrast - September 23 at 2:26 AM logoETFs with exposure to Juniper Pharmaceuticals, Inc. : September 22, 2017 - September 22 at 12:07 PM logoJuniper Pharmaceuticals, Inc. :JNP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017 - September 20 at 11:53 PM logoBRIEF-Juniper Pharmaceuticals announces strategic reprioritization - September 18 at 7:39 PM logoJuniper Pharmaceuticals Announces Strategic Reprioritization - September 18 at 7:39 PM logoJuniper Pharmaceuticals, Inc. (JNP) Given Consensus Rating of "Buy" by Analysts - September 9 at 4:30 PM logoJuniper Pharmaceuticals, Inc. (JNP) Expected to Post Quarterly Sales of $11.98 Million - August 23 at 10:04 AM logo-$0.14 Earnings Per Share Expected for Juniper Pharmaceuticals, Inc. (JNP) This Quarter - August 21 at 12:24 PM logoJuniper Pharmaceuticals, Inc. (JNP) Receives Consensus Rating of "Hold" from Brokerages - August 13 at 12:32 AM logo$12.54 Million in Sales Expected for Juniper Pharmaceuticals, Inc. (JNP) This Quarter - August 5 at 7:42 AM logoEdited Transcript of JNP earnings conference call or presentation 3-Aug-17 8:30pm GMT - August 4 at 11:13 PM logoJuniper Pharmaceuticals, Inc. (JNP) Posts Earnings Results, Beats Estimates By $0.10 EPS - August 4 at 5:46 PM logoInvestor Network: Juniper Pharmaceuticals, Inc. to Host Earnings Call - August 3 at 10:24 PM logoJuniper Pharmaceuticals Reports Second Quarter 2017 Financial and Operating Results - August 3 at 10:24 PM logoJuniper Pharmaceuticals posts 2Q loss - August 3 at 10:24 PM logoJuniper Pharmaceuticals, Inc. (JNP) Expected to Announce Earnings of -$0.13 Per Share - August 3 at 7:52 AM logoJuniper Pharmaceuticals to Report Second Quarter 2017 Results on August 3, 2017 - July 28 at 12:06 AM logoJuniper Pharmaceuticals, Inc. (NASDAQ:JNP) Given Average Rating of "Hold" by Analysts - July 19 at 12:32 AM logoJuniper Pharmaceuticals, Inc. (JNP) Rating Increased to Outperform at BMO Capital Markets - July 14 at 12:33 PM logoETFs with exposure to Juniper Pharmaceuticals, Inc. : July 13, 2017 - July 14 at 5:14 AM logo$11.84 Million in Sales Expected for Juniper Pharmaceuticals, Inc. (JNP) This Quarter - July 13 at 10:50 AM logoJuniper Pharmaceuticals, Inc. (NASDAQ:JNP) Expected to Announce Earnings of -$0.13 Per Share - July 12 at 12:04 AM logoFinancial Contrast: Juniper Pharmaceuticals (JNP) versus Patheon NV (PTHN) - July 9 at 10:26 AM logoJuniper Pharmaceuticals Announces Results of 2017 Annual Meeting - July 6 at 6:53 AM logoJuniper Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results - March 7 at 10:51 AM logoJUNIPER PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a - March 7 at 10:51 AM logoQ4 2016 Juniper Pharmaceuticals Inc Earnings Release - Before Market Open - March 7 at 10:51 AM logoLatest version of Dodd-Frank reversal bill would exempt a third of public companies from giving auditor warning - February 16 at 5:45 PM logoBRIEF-Juniper Pharma will focus on IND-enabling activities for JNP-0201 - January 6 at 6:46 PM logo8:01 am Juniper Pharma announced plans for 2017 that are expected to enable the Company to submit Investigational New Drug applications for its hormone-delivery intravaginal ring candidates in the first half of 2018 - January 6 at 6:45 PM logoBRIEF-Juniper Pharmaceuticals prototype formulation development for JNP-0301 is underway - January 5 at 7:22 PM logoJUNIPER PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, - December 23 at 6:19 PM logoJuniper Pharmaceuticals Announces Appointment of Jeffrey Young as Chief Financial Officer - PR Newswire (press release) - December 21 at 8:20 AM



Juniper Pharmaceuticals (JNP) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.